ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001445

Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease

Identifieur interne : 001445 ( PascalFrancis/Corpus ); précédent : 001444; suivant : 001446

Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease

Auteurs : M. Gentil ; C.-L. Tournier ; P. Pollak ; A. L. Benabid

Source :

European neurology [ 0014-3022 ] ; 1999.

RBID : Pascal:99-0528295

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Antiparkinsonien, Trouble langage, Stimulation instrumentale, Noyau sousthalamique, Bilatéral, Dysarthrie, Etude cas, Traitement, Homme, Chimiothérapie.

English descriptors

KwdEn :
- Antiparkinson agent, Bilateral, Case study, Chemotherapy, Dysarthria, Human, Instrumental stimulation, Language disorder, Levodopa, Parkinson disease, Subthalamic nucleus, Treatment.

Abstract

This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0014-3022`
A02	`01`			`@0 EUNEAP`
A03		`1`		`@0 Eur. neurol.`
A05				`@2 42`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease`
A11	`01`	`1`		`@1 GENTIL (M.)`
A11	`02`	`1`		`@1 TOURNIER (C.-L.)`
A11	`03`	`1`		`@1 POLLAK (P.)`
A11	`04`	`1`		`@1 BENABID (A. L.)`
A14	`01`			`@1 INSERM, U 318, Centre Hospitalier Universitaire @2 Grenoble @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 136-140`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 4507C @5 354000089768890040`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 16 ref.`
A47	`01`	`1`		`@0 99-0528295`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 European neurology`
A66	`01`			`@0 CHE`
C01	`01`		`ENG`	@0 This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @5 04`
C03	`03`	`X`	`FRE`	`@0 Antiparkinsonien @5 05`
C03	`03`	`X`	`ENG`	`@0 Antiparkinson agent @5 05`
C03	`03`	`X`	`SPA`	`@0 Antiparkinsoniano @5 05`
C03	`04`	`X`	`FRE`	`@0 Trouble langage @5 07`
C03	`04`	`X`	`ENG`	`@0 Language disorder @5 07`
C03	`04`	`X`	`SPA`	`@0 Trastorno lenguaje @5 07`
C03	`05`	`X`	`FRE`	`@0 Stimulation instrumentale @5 10`
C03	`05`	`X`	`ENG`	`@0 Instrumental stimulation @5 10`
C03	`05`	`X`	`SPA`	`@0 Estimulación instrumental @5 10`
C03	`06`	`X`	`FRE`	`@0 Noyau sousthalamique @5 11`
C03	`06`	`X`	`ENG`	`@0 Subthalamic nucleus @5 11`
C03	`06`	`X`	`SPA`	`@0 Núcleo subtalámico @5 11`
C03	`07`	`X`	`FRE`	`@0 Bilatéral @5 12`
C03	`07`	`X`	`ENG`	`@0 Bilateral @5 12`
C03	`07`	`X`	`SPA`	`@0 Bilateral @5 12`
C03	`08`	`X`	`FRE`	`@0 Dysarthrie @5 13`
C03	`08`	`X`	`ENG`	`@0 Dysarthria @5 13`
C03	`08`	`X`	`SPA`	`@0 Disartria @5 13`
C03	`09`	`X`	`FRE`	`@0 Etude cas @5 16`
C03	`09`	`X`	`ENG`	`@0 Case study @5 16`
C03	`09`	`X`	`SPA`	`@0 Estudio caso @5 16`
C03	`10`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`10`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`10`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`11`	`X`	`FRE`	`@0 Homme @5 20`
C03	`11`	`X`	`ENG`	`@0 Human @5 20`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`12`	`X`	`FRE`	`@0 Chimiothérapie @5 23`
C03	`12`	`X`	`ENG`	`@0 Chemotherapy @5 23`
C03	`12`	`X`	`SPA`	`@0 Quimioterapia @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 54`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 54`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 54`
C07	`07`	`X`	`FRE`	`@0 Trouble communication @5 55`
C07	`07`	`X`	`ENG`	`@0 Communication disorder @5 55`
C07	`07`	`X`	`SPA`	`@0 Trastorno comunicación @5 55`
C07	`08`	`X`	`FRE`	`@0 Traitement instrumental @5 61`
C07	`08`	`X`	`ENG`	`@0 Instrumentation therapy @5 61`
C07	`08`	`X`	`SPA`	`@0 Tratamiento instrumental @5 61`
N21				`@1 340`

Format Inist (serveur)

NO :	PASCAL 99-0528295 INIST
ET :	Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease
AU :	GENTIL (M.); TOURNIER (C.-L.); POLLAK (P.); BENABID (A. L.)
AF :	INSERM, U 318, Centre Hospitalier Universitaire/Grenoble/France (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	European neurology; ISSN 0014-3022; Coden EUNEAP; Suisse; Da. 1999; Vol. 42; No. 3; Pp. 136-140; Bibl. 16 ref.
LA :	Anglais
EA :	This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.
CC :	002B17G
FD :	Parkinson maladie; Lévodopa; Antiparkinsonien; Trouble langage; Stimulation instrumentale; Noyau sousthalamique; Bilatéral; Dysarthrie; Etude cas; Traitement; Homme; Chimiothérapie
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Trouble communication; Traitement instrumental
ED :	Parkinson disease; Levodopa; Antiparkinson agent; Language disorder; Instrumental stimulation; Subthalamic nucleus; Bilateral; Dysarthria; Case study; Treatment; Human; Chemotherapy
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Communication disorder; Instrumentation therapy
SD :	Parkinson enfermedad; Levodopa; Antiparkinsoniano; Trastorno lenguaje; Estimulación instrumental; Núcleo subtalámico; Bilateral; Disartria; Estudio caso; Tratamiento; Hombre; Quimioterapia
LO :	INIST-4507C.354000089768890040
ID :	99-0528295

Links to Exploration step

Pascal:99-0528295

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease</title>
<author><name sortKey="Gentil, M" sort="Gentil, M" uniqKey="Gentil M" first="M." last="Gentil">M. Gentil</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tournier, C L" sort="Tournier, C L" uniqKey="Tournier C" first="C.-L." last="Tournier">C.-L. Tournier</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A. L." last="Benabid">A. L. Benabid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0528295</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0528295 INIST</idno>
<idno type="RBID">Pascal:99-0528295</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001445</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease</title>
<author><name sortKey="Gentil, M" sort="Gentil, M" uniqKey="Gentil M" first="M." last="Gentil">M. Gentil</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tournier, C L" sort="Tournier, C L" uniqKey="Tournier C" first="C.-L." last="Tournier">C.-L. Tournier</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A. L." last="Benabid">A. L. Benabid</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European neurology</title>
<title level="j" type="abbreviated">Eur. neurol.</title>
<idno type="ISSN">0014-3022</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European neurology</title>
<title level="j" type="abbreviated">Eur. neurol.</title>
<idno type="ISSN">0014-3022</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Bilateral</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Dysarthria</term>
<term>Human</term>
<term>Instrumental stimulation</term>
<term>Language disorder</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Subthalamic nucleus</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Trouble langage</term>
<term>Stimulation instrumentale</term>
<term>Noyau sousthalamique</term>
<term>Bilatéral</term>
<term>Dysarthrie</term>
<term>Etude cas</term>
<term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0014-3022</s0>
</fA01>
<fA02 i1="01"><s0>EUNEAP</s0>
</fA02>
<fA03 i2="1"><s0>Eur. neurol.</s0>
</fA03>
<fA05><s2>42</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GENTIL (M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TOURNIER (C.-L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>POLLAK (P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BENABID (A. L.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1>
<s2>Grenoble</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>136-140</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>4507C</s2>
<s5>354000089768890040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0528295</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>European neurology</s0>
</fA64>
<fA66 i1="01"><s0>CHE</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Trouble langage</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Language disorder</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Trastorno lenguaje</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Stimulation instrumentale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Instrumental stimulation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estimulación instrumental</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Noyau sousthalamique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Subthalamic nucleus</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Núcleo subtalámico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Bilatéral</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Bilateral</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Bilateral</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Dysarthrie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Dysarthria</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Disartria</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Case study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>54</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>54</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>54</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble communication</s0>
<s5>55</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Communication disorder</s0>
<s5>55</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno comunicación</s0>
<s5>55</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Traitement instrumental</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Instrumentation therapy</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Tratamiento instrumental</s0>
<s5>61</s5>
</fC07>
<fN21><s1>340</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0528295 INIST</NO>
<ET>Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease</ET>
<AU>GENTIL (M.); TOURNIER (C.-L.); POLLAK (P.); BENABID (A. L.)</AU>
<AF>INSERM, U 318, Centre Hospitalier Universitaire/Grenoble/France (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>European neurology; ISSN 0014-3022; Coden EUNEAP; Suisse; Da. 1999; Vol. 42; No. 3; Pp. 136-140; Bibl. 16 ref.</SO>
<LA>Anglais</LA>
<EA>This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Lévodopa; Antiparkinsonien; Trouble langage; Stimulation instrumentale; Noyau sousthalamique; Bilatéral; Dysarthrie; Etude cas; Traitement; Homme; Chimiothérapie</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Trouble communication; Traitement instrumental</FG>
<ED>Parkinson disease; Levodopa; Antiparkinson agent; Language disorder; Instrumental stimulation; Subthalamic nucleus; Bilateral; Dysarthria; Case study; Treatment; Human; Chemotherapy</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Communication disorder; Instrumentation therapy</EG>
<SD>Parkinson enfermedad; Levodopa; Antiparkinsoniano; Trastorno lenguaje; Estimulación instrumental; Núcleo subtalámico; Bilateral; Disartria; Estudio caso; Tratamiento; Hombre; Quimioterapia</SD>
<LO>INIST-4507C.354000089768890040</LO>
<ID>99-0528295</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001445 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001445 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0528295
   |texte=   Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease

Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri